Accéder au contenu
Merck

[An experimental study of the efficiency of cycloferon in the complex chemotherapy of generalized drug-resistant tuberculosis].

Eksperimental'naia i klinicheskaia farmakologiia (2012-11-20)
D S Sukhanov, T I Vinogradova, S N Demidik, A V El'kin, N V Zabolotnykh, S N Vasil'eva, M L Vitovskaia, M G Romantsov
RÉSUMÉ

The results of an experimental study of the efficiency of cycloferon included in a complex chemotherapy of generalized drug-resistant mycobacterium tuberculosis (MBT) are presented. It is established that cycloferon (3.6 mg/kg) produces a significant therapeutic effect, which is manifested by an increase in the lung clearance from MBT, a decrease in the spread of specific inflammation in the lungs, and the disappearance of MBT-induced alterations. In addition, activation of the signs of tension in the local immunity of lung tissues is observed as manifested by changes in the cellular composition of granulomas and more frequent detection of large lymphocytic and macrophage infiltration. The administration of cycloferon significantly increases the absorptive and digestive activity of phagocytosis by peritoneal macrophages, which has been inhibited during the development of experimental MBT infection.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
9-Oxo-10(9H)-acridineacetic acid, for HPLC derivatization, ≥99.0% (T)